Peer-reviewed veterinary case report
c-kit and TP53 gene mutations in dog mast cell tumors and what they
By Vozdova, Miluse et al.·Published in Veterinary journal (London, England : 1997)·2019·Central European Institute of Technology-Veterinary Research Institute·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
- Species:
- dog
Plain-English summary
A study looked at skin tumors called mast cell tumors (MCT) in dogs, which are common but can behave unpredictably. Researchers found that about 19.5% of the tumors had mutations in a gene called c-kit, which was linked to more aggressive tumors. However, mutations in another gene, TP53, were present in 14.6% of the tumors but didn't help predict how the tumors would behave. This means that while some genetic changes can indicate a more serious tumor, others may not provide useful information for treatment decisions.
People also search for: dog mast cell tumor treatment · c-kit mutation in dogs · prognosis for dog skin tumors
Abstract
Cutaneous mast cell tumours (MCT) are among the most frequent malignancies in dogs. Their clinical behaviour is highly variable and, with the exception of mutations in the c-kit gene, little is known about their genetic aetiology. The mutational status of the c-kit exons 8, 9 and 11, and exons 5-8 of the TP53 gene was analysed to find markers for molecular stratification of MCTs and predictors of clinical outcome. Mutations in the c-kit gene were detected in 19.5% (n = 8/41) samples and their presence was significantly associated with the high histopathological grade (P = 0.038). Mutations in the DNA binding domain of the TP53 gene were found in 14.6% (n = 6/41) of the analysed MCTs, and their frequency was similar in low and high grade MCTs (P > 0.05). TP53 mutations were not useful prognostic factors in this sample of canine cutaneous MCTs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30971355/